Rona Licenses ALK7 Obesity RNAi Candidate to Roche in $1.16B Deal
Santa Barbara – October 13, 2026 -- Rona Therapeutics will receive up to $100 million in upfront and near-term milestone payments from Roche under an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7), with potential for a further $1.06 billion in milestones.
Rona is eligible for $1.06 billion in milestones plus tiered royalties
The additional $1.06 billion covers development, regulatory and commercial milestones. Rona is also eligible for tiered royalties on global net sales. Combined with the upfront and near-term payments, headline deal value reaches roughly $1.16 billion if all milestones are met.
The candidate uses Rona's proprietary extrahepatic delivery platform, which targets tissue outside the liver. Roche (SIX: RO, ROG; OTCQX: RHHBY) receives the exclusive license for the asset worldwide.